Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
As any person with cancer knows, a cancer diagnosis also affects family members and friends. Sometimes, the complex feelings and lifestyle changes caused by cancer and its treatment become as overwhelming for others in your life as they are for you. Cancer has the greatest effect on marriages and....
A benign tumor means it’s not cancer. These tumors don’t spread to other parts of the body and are usually not life-threatening. However, depending on their size or location, they may need to be removed if they press on important organs or cause discomfort.
No, not every cancer patient needs chemotherapy. Treatment depends on the type and stage of cancer. Some may need surgery, radiation, or newer therapies like immunotherapy. Your doctor will recommend the best plan for your condition. I’m scared chemotherapy will make me lose my hair. Is there any....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
Reviewed by:Dr. Nitika Sharma - BDS
Reviewed by:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.